When was BridGene Biosciences founded?

BridGene Biosciences was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is BridGene Biosciences located?

BridGene Biosciences is headquartered in Sunnyvale, United States.

Who is the current CEO of BridGene Biosciences?

Ping Cao of BridGene Biosciences. They have also founded 1 company.

How many employees does BridGene Biosciences have?

As of Feb 28, 2026, the latest employee count at BridGene Biosciences is 30.

Is BridGene Biosciences a funded company?

BridGene Biosciences is a funded company, having raised a total of $78.5M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 15, 2018.

When was the latest funding round of BridGene Biosciences?

BridGene Biosciences' latest funding was a $***** Series B round on Oct 16, 2025, with participation from 5 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $182M in funding in 2026 to date.

Where does BridGene Biosciences rank among its competitors?

BridGene Biosciences ranks 175th amongst 3138 active competitors, of which 874 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was BridGene Biosciences, which secured $28M in Oct, 2025.

Who are the top competitors of BridGene Biosciences?

BridGene Biosciences' top competitors include Sana Biotechnology, Juno Therapeutics and Spark Therapeutics. Among them, BridGene Biosciences secured the most recent funding round in October, 2025.

BridGene Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small-molecule drugs for the treatment of cancer. The company utilizes its proprietary Chemoproteomics platform, IMTAC that enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases.

Website: www.bridgenebio.com
Social
Email ID: *****@bridgenebiosciences.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Sunnyvale, United States

Stage

Series B

Total Funding

$78.5M in 5 rounds

Latest Funding Round

Series B, Oct 16, 2025, $*****

Investors

Deyi Capital & 8 more

Ranked

175^th among 3138 active competitors

Employee Count

30 as on Feb 28, 2026

Similar Companies

Sana Biotechnology & 4215 more

View BridGene Biosciences' full profile

BridGene Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BRIDGENE BIOSCIENCES INC CIN: 830552264 , United States, Active	Dec 31, 1999	-	24 (As on Dec 31, 2024)	-
BridGene Biosciences, Inc. CIN: 83-0552264 , United States, Active	Dec 31, 2018	-	15 (As on Dec 31, 2021)	-

BridGene Biosciences has raised a total funding of $78.5M over 5 rounds. Its first funding round was on Sep 15, 2018. Its latest funding round was a Series B round on Oct 16, 2025 for $*****. 5 investors participated in its latest round. BridGene Biosciences has 9 institutional investors.

Here is the list of recent funding rounds of BridGene Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 16, 2025	8929884	Series B	6417256	5010520	3597035	6701395
Jul 27, 2022	4160658	Series B	5112756	8097012	2685758	1585196
May 05, 2021	5752065	Series A	6475248	3395812	Kaitai Capital Management	9094969

Access funding benchmarks and valuations. Sign up today!

View details of BridGene Biosciences's funding rounds and investors

The founders of BridGene Biosciences are Ping Cao and Irene Yuan. Ping Cao is the CEO of BridGene Biosciences.

Here are the details of BridGene Biosciences' key team members:

Ping Cao: Co-Founder & CEO of BridGene Biosciences.
Contact Info: 1 email address
Irene Yuan: Co-Founder & Executive Vice President of BridGene Biosciences.
Contact Info: 1 email address

View details of BridGene Biosciences's Founder profiles and Board Members

BridGene Biosciences' employee count trend

BridGene Biosciences has 30 employees as of Feb 26. Here is BridGene Biosciences's employee count trend over the years:

Employee count trend for BridGene Biosciences

Uncover BridGene Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BridGene Biosciences include Sana Biotechnology, Juno Therapeutics and Spark Therapeutics. Here is the list of Top 10 competitors of BridGene Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
2nd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	72/100
5th	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
6th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
7th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
8th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Advent Life Sciences, 4Bio Capital & 11 others	70/100
9th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
10th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
175th	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	GTJAI, Deyi Capital & 7 others	57/100